Mabura (adalimumab biosimilar)
/ Hetero
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 11, 2020
Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero's adalimumab (Mabura®, Hetero Biopharma Ltd.) and reference adalimumab (Humira®, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy.
(PubMed, BMC Rheumatol)
- "Results demonstrated Hetero's adalimumab is as effective and well tolerated as reference adalimumab in patients with active RA concomitantly on MTX therapy. CTRI/2016/04/006884, Registered on 28/04/2016."
Clinical • Journal • PK/PD data • Immunology • Rheumatoid Arthritis • Rheumatology • Sinusitis • CRP
1 to 1
Of
1
Go to page
1